CryoCell Ebit Per Revenue from 2010 to 2024

CCEL Stock  USD 8.67  0.42  4.62%   
CryoCell International Ebit Per Revenue yearly trend continues to be quite stable with very little volatility. The value of Ebit Per Revenue is projected to decrease to -0.37. From the period between 2010 and 2024, CryoCell International, Ebit Per Revenue regression line of its data series had standard deviation of  0.23 and standard deviation of  0.23. View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
(0.35)
Current Value
(0.37)
Quarterly Volatility
0.22758396
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CryoCell International financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CryoCell International's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Selling General Administrative of 11.2 M or Total Revenue of 18.4 M, as well as many indicators such as Price To Sales Ratio of 1.56, Dividend Yield of 0.2 or Days Sales Outstanding of 79.26. CryoCell financial statements analysis is a perfect complement when working with CryoCell International Valuation or Volatility modules.
  
Check out the analysis of CryoCell International Correlation against competitors.
For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.

Latest CryoCell International's Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of CryoCell International over the last few years. It is CryoCell International's Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CryoCell International's overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Slightly volatile
   Ebit Per Revenue   
       Timeline  

CryoCell Ebit Per Revenue Regression Statistics

Arithmetic Mean0.03
Geometric Mean0.16
Coefficient Of Variation703.01
Mean Deviation0.18
Median0.13
Standard Deviation0.23
Sample Variance0.05
Range0.6888
R-Value(0.57)
Mean Square Error0.04
R-Squared0.32
Significance0.03
Slope(0.03)
Total Sum of Squares0.73

CryoCell Ebit Per Revenue History

2024 -0.37
2023 -0.35
2022 -0.39
2021 0.13
2019 0.25
2018 0.16
2017 0.18

About CryoCell International Financial Statements

CryoCell International investors utilize fundamental indicators, such as Ebit Per Revenue, to predict how CryoCell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Ebit Per Revenue(0.35)(0.37)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether CryoCell International is a strong investment it is important to analyze CryoCell International's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CryoCell International's future performance. For an informed investment choice regarding CryoCell Stock, refer to the following important reports:
Check out the analysis of CryoCell International Correlation against competitors.
For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.625
Earnings Share
(1.07)
Revenue Per Share
3.89
Quarterly Revenue Growth
0.025
Return On Assets
(0)
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.